A collectibles category few investors were watching just drove GameStop's most profitable second quarter ever, and a director moved seven figures into the stock the same morning results dropped.
SanDisk has turned into one of the most violent momentum trades of the cycle, surging over 600% in under a year on an AI storage bull case that looks genuinely compelling and…
TPG just bought into the exact Optum clinics that derailed UnitedHealth's profits, and management is hours away from reaffirming guidance that could either validate the deal or reopen a wound investors hoped…
Jim Cramer told a caller that playing it safe with bonds can be the most dangerous move a young investor makes, and five years of market data back him up in a…
Nebius just auctioned its first Blackwell capacity above any price it has ever charged, and management says it could sell all of 2027 right now but is choosing not to. Whether that…
Apple's new CEO John Ternus faces his first real test before he has even settled in, as customers weigh whether to absorb two price increases inside two weeks or simply sit out…
Fastly is surging 7% on a session when the cloud sector and broad market are both sliding, and no news, analyst call, or catalyst explains the move. The reason behind the rally…
Meta just attached a price tag to its AI ambitions, and traders are now asking whether a consumer subscription can justify one of the biggest capital budgets in tech history while a…
Salesforce bulls are pointing to an AI monetization curve that is bending sharply upward, but the bears have real ammunition too, and with Dreamforce and Investor Day arriving next week, the stock…
Oracle has shed a third of its value while booking a backlog that no software company has ever matched, and the reason that gap exists is exactly what divides Wall Street right…
Invesco offers two funds tracking the exact same Nasdaq-100 stocks with the same management team, yet one of them quietly drains thousands of dollars from a long-term investor's portfolio. Knowing which ticker…
Three S&P 500 covered-call ETFs promise income from the same underlying index, but their wildly different strategies produce returns that would shock anyone who chose a fund based on yield alone.
Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same…
One S&P 500-based ETF has quietly been outpacing both the SPY and the QQQ year after year, and the structural reason behind its edge suggests the run is far from over.
A Texas factory just handed Enphase a credible claim on the AI data-center power market, and SolarEdge surged even harder despite announcing nothing at all.
